Reading ESPR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ESPR free→Reading ESPR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ESPR free→QuarterlyIQ Insights · ESPR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. As previously disclosed, on May 1, 2026, Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Essence Parent Inc., a Delaware corporation and an affiliate of ArchiMed SAS (“Parent”), and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (“MergerCo”), pursuant to which, subject to the terms and conditions thereof, MergerCo will merge with and into the Compa…
Importance-ranked changes since the prior daily snapshot.
Company momentum fell by 23.2 points (from -42.0 to -65.2).
Confidence changed from 'high' to 'medium'.
Row flagged provisional (some sub-scores became unavailable).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.